Serologically diagnosed infection with human papillomavirus type 16 and risk for subsequent development of cervical carcinoma: nested case-control study.
case_control · Level III
Where this comes from
- Record sourced from PubMed, PMID 8595281.
- Also identified by PMC identifier 2350335.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
To study human papillomavirus type 16 in the aetiology of cervical carcinoma. Within a cohort of 18814 Finnish women followed up to 23 years a nested case-control study was conducted based on serological diagnosis of past infection with human papillomavirus type 16. 72 women (27 with invasive carcinoma and 45 with in situ carcinoma) and 143 matched controls were identified during the follow up. Relative risk of cervical carcinoma in presence of IgG antibodies to human papillomavirus type 16. After adjustment for smoking and for antibodies to various other agents of sexually transmitted disease, such as herpes simplex virus type 2 and Chlamydia trachomatis, the only significant association was with infection with human papillomavirus type 16 (odds ratio 12.5; 95% confidence interval 2.7 to 57, 2P<0.001). This prospective study provides epidemiological evidence that infection with human papillomavirus type 16 confers an excess risk for subsequent development of cervical carcinoma.
Medical subject headings
- Papillomaviridae
- Papillomavirus Infections
- Tumor Virus Infections
- Uterine Cervical Neoplasms